The elephant in the room
Ne umquam pars pro toto (Plinius). Can anyone remember a bit of Latin? This quotation was used in a slide presentation given a few weeks ago by Louis Denis, urologist and prostate cancer patient, at [more]
Editorial
Improving outcomes the St Gallen way
This issue comes out as breast cancer specialists from around the world gather in Vienna for the 15th biannual St Gallen International Breast Cancer Conference, to discuss what we’ve learnt over the past two years about [more]
Umberto Veronesi’s legacy
With the death of Umberto Veronesi last November, the cancer world has lost one of its great leaders, and we at the European School of Oncology have lost our inspiration and founder. In this issue [more]
Umberto Veronesi 1925-2016
Umberto Veronesi passed away on the 8th of November, after an entire life dedicated to the fight against cancer, to surgery, to advocacy, to research. He died in peace, fading away with his unique and [more]
Old, young – does it matter?
Not so long ago, research protocols excluded older cancer patients based on chronologic age. Now they exclude patients with comorbidities, and as most older patients suffer additional ailments, they do not fit the protocols. But [more]
The more you treat, the more you cure? Challenging the dogma
I was lucky enough to be in the right place at the right time to witness one of the great turning points in our approach to cancer. In March 1973, a medical student at Milan [more]
Time to refocus on risk and prevention
“In the history of cancer research, there has always been tension between those who want to treat cancer and those who think we should prevent it,” writes the pioneering medical oncologist and former head of the [more]
Personalising treatments: lessons from history
Fifty years ago, when I was just starting out in cancer medicine, our team at the cancer centre attached to Berlin’s Academy of Sciences began our attempts to individualise chemotherapy treatments. We knew that response [more]
Turning more than one page
We at ESO are turning important pages in the history of our service to the European cancer community. We now invite you to turn the pages of Cancer World, which we hope you will find [more]
Our keywords
In this editorial, Alberto Costa, who has taken over from Kathy Redmond, pays tribute to her achievements, reaffirms the magazines founding principles, and flags up changes to style and content that will expand the reach [more]
Goodbye or arrivederci?
Our new vocabulary gene, genome, molecular, targeted, personalised no longer inspires the confidence it once did, and as the cancer community prepares to gather at the 18th ECCO – 40th ESMO European Cancer [more]
No easy road to outsmart cancer
Hopes of greatly speeding up the evaluation of new therapies by using tumour response to a short course of neoadjuvant treatment as a surrogate for clinical benefit have proved false and the sooner we recognise [more]
They are many, will we be too few?
The European Commission is predicting that by 2020 Europe will need an additional one million clinical professionals to care for its ageing population. With many of our cancer systems already working at full capacity, this [more]